Celgene loses Revlimid patent in EU; Biogen to buy back $5B in shares;

@FiercePharma: Japan's Eisai makes moves for Indian API manufacturing in further cost trimming. FiercePharmaAsia story | Follow @FiercePharma

@CarlyHFierce: ICYMI: Valeant chief Pearson the next Warren Buffett? Deal partner Ackman thinks so. Story | Follow @CarlyHFierce

> Celgene ($CELG) says a decision by the EU patent office could mean generics of its $5 billion cancer drug Revlimid might be on the market there a year or two sooner than the previously projected 2024. Story

> Biogen ($BIIB) intends to buy back up to $5 billion in shares. Report

> Events and information group CPhI has set up a relationship with international aid group GlobalAngels, that allows pharmaceutical companies to work with the charity in a number of ways. Release

> Abuse of Endo International's opioid Opana has been tied to an increase in hepatitis C infections among drug addicts. Story

> The California Supreme Court has found that some so-called pay-for-delay settlements between drug companies may be illegal. Story

Medical Device News

@FierceMedDev: Adaptive Biotechnologies reels in $195M for immunosequencing tech. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: ICYMI yesterday: Smith & Nephew boosts rep-less sales pilot by acquiring software assets that help automate training. Article | Follow @VarunSaxena2

@EmilyWFierce: ICYMI: RainDance shoots for long reads of whole genome with Pac Bio collaboration. Item | Follow @EmilyWFierce

> Mayo Clinic study finds digital health interventions reduce risk of cardiovascular disease. More

> Fitbit files for up to $100M IPO as it dominates fitness wearables and aims for corporate wellness. Story

> Smartphone-based diagnostic device detects parasitic worms via video. News

Biotech News

@FierceBiotech: La Jolla dumps its NASH drug and shifts its focus to rare disease. Report | Follow @FierceBiotech

@JohnCFierce: My thought: FDA panels lean on the side of approval, especially for a disease like CF. Any ??? can be answered post approval. $VRTX wins. | Follow @JohnCFierce

> MorphoSys bags a peptide biotech for $22M. Item

> FDA review challenges Vertex's case for crucial cystic fibrosis combo. Article

> Phase I safety scare costs TetraLogic a $25M fundraise. News

And Finally... The World Health Organization said Friday that naming new diseases after places, animal species or people can be stigmatizing and recommended that the names include "generic descriptive terms" instead. More

Suggested Articles

After years of having first-line liver cancer market to itself, Bayer’s Nexavar is getting major competition from Roche's Tecentriq.

Most of the recent enthusiasm around AbbVie’s new drugs has centered on Skyrizi and Rinvoq, but elagolix wants a piece of the spotlight, too.

During David Loew's tenure, Sanofi Pasteur bought Protein Sciences, whose recombinant technology is being applied to a COVID-19 vaccine.